
Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.
In Episode 21 of
They also talk about:
Disclaimer: The views and opinions expressed in this podcast are those of the speakers and guests and do not necessarily reflect the views or positions of the Bladder Cancer Advocacy Network.






